Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.1%. By the end of trading, Gilead fell $2.38 (-3.2%) to $72.81 on heavy volume. Throughout the day, 25,701,651 shares of Gilead exchanged hands as compared to its average daily volume of 8,913,000 shares. The stock ranged in price between $70.23-$75.10 after having opened the day at $75.00 as compared to the previous trading day's close of $75.19. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 42.9%, TG Therapeutics ( TGTX), down 10.5%, NuPathe ( PATH), down 10.4% and Cyclacel Pharmaceuticals ( CYCC), down 10.4%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $113.5 billion and is part of the health care sector. The company has a P/E ratio of 40.6, above the S&P 500 P/E ratio of 17.7. Shares are up 104.7% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Enanta Pharmaceuticals ( ENTA), up 28.6%, Relypsa ( RLYP), up 16.6%, Acceleron Pharma ( XLRN), up 9.8% and Xencor ( XNCR), up 9.6% , were all gainers within the drugs industry with Incyte ( INCY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists